Vagus nerve stimulation (VNS) paired with rehabilitation has become one of the most significant advances in stroke recovery in the past decade. Unlike traditional VNS for epilepsy or depression, which delivers continuous stimulation, paired VNS times short electrical bursts to coincide with specific movements during physical therapy. The result is a targeted neuroplasticity tool that has now earned FDA clearance, demonstrated durable two-year outcomes, and been incorporated into updated AHA stroke guidelines. This article covers the science, the clinical evidence, the device, and what stroke survivors need to know.
Why the Vagus Nerve Matters for Stroke Recovery
After an ischaemic stroke, brain tissue supplied by the blocked artery dies. The surrounding penumbral tissue survives but is often functionally impaired. Recovery depends on neuroplasticity: the brain’s ability to reorganise, recruit intact circuits, and form new synaptic connections to compensate for lost function.
Neuroplasticity is not limitless, and it tends to be most active in the early months after stroke. For chronic stroke survivors (more than six months post-stroke), the window of spontaneous recovery has largely closed. Traditional rehabilitation in this phase typically produces modest gains. This is where VNS enters the picture.
When the vagus nerve is electrically stimulated, it triggers the release of neuromodulators in the brain, including norepinephrine from the locus coeruleus and acetylcholine from the basal forebrain. These neurotransmitters are key regulators of synaptic plasticity. By pairing vagal stimulation with specific rehabilitation movements, clinicians can time the release of these neuromodulators to coincide with the exact neural circuits being exercised, strengthening those pathways preferentially.
The VNS-REHAB Trial
The pivotal clinical evidence comes from the VNS-REHAB trial, a multi-centre, triple-blinded, sham-controlled randomised study published in The Lancet in 2021. The trial enrolled 108 chronic ischaemic stroke survivors who averaged approximately three years post-stroke and had persistent upper extremity impairment.
Participants were randomised to receive either active VNS paired with intensive upper extremity rehabilitation or sham stimulation paired with the same rehabilitation protocol. The primary outcome was the change in Fugle-Meyer Assessment for the Upper Extremity (FMA-UE), a standardised measure of motor impairment.
The results showed that approximately twice as many patients in the active VNS group achieved clinically meaningful upper extremity improvement compared to the sham group. Nearly half of the active VNS group met the threshold for a clinically meaningful response.
Two-Year Follow-Up Data
Long-term outcomes from the trial were published in Neurology in 2026. In the 49 participants analysed at two years, the average FMA-UE improvement was 7.5 points from baseline, exceeding the minimum clinically important difference of 6 points. The responder rate was 76% on the FMA-UE and/or the Wolf Motor Function Test (WMFT). WMFT scores improved by an average of 0.63 points, also above the clinical threshold of 0.4.
Statistically significant improvements were also reported on the Stroke Impact Scale for activities of daily living (SIS-ADL), SIS-Hand, Motor Activity Log (MAL), and Stroke-Specific Quality of Life (SS-QOL). A subset of participants continued to improve between years one and two, suggesting that the neuroplastic changes facilitated by paired VNS may continue evolving with ongoing therapy. One-year data published in Stroke in 2025 had already shown maintained improvements.
No long-term serious adverse events related to the therapy or stimulation were reported through two years of follow-up.
Your local vagus nerve experts
Find a vagus nerve practitioner near you
Our directory lists 2,684 practitioners across the US, from polyvagal-informed therapists to HRV biofeedback clinics.
Or browse by approach
- Polyvagal-informed therapy
- Somatic therapy
- HRV biofeedback
- Craniosacral therapy
- Breathwork
- Insomnia therapy (CBT-I)
The directory covers the United States for now. Listings come from practitioners’ own websites and are not endorsements or medical advice. Browse the full directory.
The Vivistim System
The FDA-cleared device for paired VNS in stroke is the Vivistim Paired VNS System, developed by Mobia Medical (formerly MicroTransponder). The system involves surgical implantation of a small pulse generator, similar to a cardiac pacemaker, in the upper chest below the clavicle. A stimulation lead is wrapped around the left vagus nerve at the level of the cricoid cartilage through a small neck incision, and tunnelled under the skin to connect to the generator.
The implantation procedure takes approximately 60 to 90 minutes under general anaesthesia and is typically performed as an outpatient surgery. Patients must be at least six months post-ischaemic stroke.
Unlike continuous VNS devices used for epilepsy, the Vivistim system delivers stimulation only during rehabilitation sessions. The patient or therapist activates the device by waving a small external wand over the chest-implanted generator. Stimulation intensity is set just below the level that causes hoarseness or a pulling sensation at the nerve.
The Rehabilitation Protocol
The paired VNS rehabilitation protocol involves an intensive phase of six weeks of in-clinic therapy, typically three sessions per week lasting approximately 90 minutes each, plus daily 30-minute home sessions. During each session, the therapist pairs short bursts of vagal stimulation with specific upper extremity movements, repeating task-specific exercises hundreds of times per session.
After the intensive phase, patients continue with home therapy sessions with the stimulator activated. The clinical team typically includes a stroke neurologist, neurosurgeon, occupational therapist, and physiatrist.
AHA Guideline Recognition
In August 2026, the American Heart Association and American Stroke Association published updated guidelines for adult stroke rehabilitation and recovery in Stroke. The 2026 guideline states that VNS paired with high-dose task-specific training may be considered to improve upper-limb function and impairment for eligible chronic stroke patients. This marked the first inclusion of paired VNS in formal stroke rehabilitation guidelines.
Who Is a Candidate?
Based on the VNS-REHAB trial criteria and current clinical practice, candidates for paired VNS therapy typically need to meet these conditions:
Stroke type. Ischaemic stroke (not haemorrhagic, as this population was not studied in the pivotal trial).
Timing. At least six months post-stroke. The trial enrolled patients averaging about three years post-stroke, so it is specifically designed for the chronic phase where conventional rehabilitation alone has limited benefit.
Residual function. Some remaining voluntary movement in the affected upper extremity. The therapy requires the patient to actively perform rehabilitation exercises during stimulation.
Motivation. High motivation and ability to participate in an intensive, structured rehabilitation programme.
Medical fitness. Ability to undergo a surgical procedure under general anaesthesia.
Limitations and Open Questions
Paired VNS is a promising but still evolving treatment. Several important limitations and unanswered questions remain.
The therapy requires surgery with all attendant risks, including infection, device malfunction, and stimulation-related side effects such as temporary hoarseness. The VNS-REHAB trial reported common side effects including hoarseness, coughing, and shortness of breath, which were generally mild and temporary.
The optimal duration of paired VNS use and the timing of peak benefit are still being studied. It is not yet clear whether stimulation should continue indefinitely or can be discontinued after a treatment phase.
The trial studied upper extremity rehabilitation only. Anecdotal reports from clinical practice suggest potential benefits for lower extremity function and speech recovery, but these require further controlled trials before they can be considered evidence-based indications.
The device requires a specialised clinical team and is currently available only at select rehabilitation centres. Access and cost may be barriers for many stroke survivors.
The Bigger Picture
Paired VNS represents a broader shift in how the vagus nerve is understood in neuroscience. Rather than simply being a nerve that regulates heart rate and digestion, the vagus nerve is increasingly recognised as a neuromodulatory gateway that can be harnessed to enhance brain plasticity. The success of paired VNS in stroke has opened research into its application in traumatic brain injury, spinal cord injury, tinnitus, and post-traumatic stress disorder.
For stroke survivors who have plateaued in their recovery, the emergence of paired VNS as a clinically validated option is a genuinely significant development, perhaps the most concrete clinical application of vagus nerve science to date.
Want to understand the full scope of how vagus nerve science is transforming medicine? Get the My Vagus Nerve & Me eBook for a comprehensive guide to the vagus nerve’s role across every major body system and the latest stimulation technologies.




